{
    "Overall_score": {
        "Correlation": 8,
        "Sentiment": 6,
        "Importance": 7,
        "Impact": 6,
        "Duration": 5,
        "Virality": 4,
        "Source_Score": 7,
        "Specificity": 7,
        "Sector_Spread": 5,
        "Tech_Mentions": 3
    },
    "Each_item": [
        {
            "News_content": "FDA staff sounds encouraging note on Celltrion's biosim of J&J blockbuster Remicade",
            "Correlation": 9,
            "Sentiment": 8,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 3,
            "Source_Score": 8,
            "Specificity": 9,
            "Sector_Spread": 6,
            "Tech_Mentions": 2
        },
        {
            "News_content": "Would YOU trust $JNJ with MASSIVE FLOOD OF GLOBAL LAWSUITS?",
            "Correlation": 7,
            "Sentiment": 3,
            "Importance": 6,
            "Impact": 5,
            "Duration": 4,
            "Virality": 7,
            "Source_Score": 5,
            "Specificity": 4,
            "Sector_Spread": 4,
            "Tech_Mentions": 1
        },
        {
            "News_content": "BUY #Johnson & Johnson, $JNJ. Target: 100.72 (+0.18%).",
            "Correlation": 8,
            "Sentiment": 9,
            "Importance": 5,
            "Impact": 6,
            "Duration": 5,
            "Virality": 5,
            "Source_Score": 6,
            "Specificity": 8,
            "Sector_Spread": 3,
            "Tech_Mentions": 4
        }
    ]
}